Toursynbio is an AI-native biopharmaceutical company dedicated to building an Autonomous AI Biopharma Foundry and transforming drug discovery into drug creation. By integrating artificial intelligence with automated experimentation, Toursynbio is redefining how biologic medicines are designed, validated, and developed.
At the core of the company’s innovation is its proprietary ToursynClaw Scientific Superintelligent Agent Platform for biologics. The platform powers a closed-loop R&D engine that seamlessly connects AI-driven molecular design, automated wet-lab validation, and continuous data feedback, creating a self-improving development cycle. Using this integrated workflow, antibody design and functional validation can be completed in as little as 1.5 months.
To date, Toursynbio has advanced 16 antibody programs through PCC-stage validation within six months and generated leading experimental results against highly challenging targets, including GPCRs and intrinsically disordered protein regions. As one of the few biotechnology companies in China to fully integrate AI computing with automated laboratory infrastructure, Toursynbio is building an AI-powered biologics foundry that accelerates therapeutic innovation and establishes a new paradigm for biopharmaceutical R&D.
Challenge
Scientific Superintelligence Agents
Scientific superintelligence agents integrate foundation models, domain-specific tools, autonomous reasoning, and experimental feedback. By connecting molecular design, experimental validation, and iterative optimization in one workflow, they accelerate scientific discovery and biopharmaceutical R&D.
Dry-Wet Iterative Laboratory
Our integrated computational–experimental laboratory connects design with validation, creating a closed loop of testing, data feedback, and model iteration to accelerate candidate discovery and optimization.
De Novo Design
Starting from target structures and functional requirements, our de novo design technology generates functional proteins with novel sequences and structures, providing new molecular solutions for complex and traditionally difficult-to-drug targets.
Team
Toursynbio is committed to accelerating R&D of scientific products through superintelligent technology, with applications in novel design of biological and material products.
2026-10-29Toursynbio to Participate in Hong Kong FinTech Week 2026, with CEO Wang Yuguang to Explore AI Applications Across Drug Modalities
2026-10-27Toursynbio 2027 Campus Recruitment | Meet Us at SJTU
2026-10-27Repost | Science as Our Torch, Marching Toward the Globe! BiG 12th Anniversary Summit Concludes on a High Note, Forging Industry Consensus at the Frontier
2026-10-25Toursynbio to Share Its Approach to Autonomous AI Biopharma R&D at the 17th Shanghai Computer-Aided Drug Design Symposium
2026-10-25Toursynbio to Attend HKEX Healthcare Summit 2026, Exploring the Future of Healthcare Innovation
2026-10-24Toursynbio Invites You to BioPlus-Interphex Korea 2026 | Oct 28–30, Meet in Seoul